LumiraDx
Delivers connected diagnostics and diagnostic-led care solutions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 7.8x EV/Revenue 72.2x EV/EBITDA | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $14.2m | Grant | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 501 % | 203 % | (40 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (550 %) | (85 %) | 11 % | (107 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (574 %) | (173 %) | (24 %) | (177 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 374 % | 77 % | 31 % | 56 % |
Source: Company filings or news article
Related Content
LumiraDx operates as a next-generation point-of-care diagnostics company, focusing on delivering high-sensitivity and high-throughput testing solutions. The company primarily serves healthcare providers and laboratories, offering a platform that supports rapid nucleic acid amplification technology. LumiraDx's business model revolves around the development and distribution of diagnostic tools, including the FDA Emergency Use Authorized SARS CoV 2 RNA STAR Complete, which facilitates high-throughput and asymptomatic testing. Revenue is generated through the sale of diagnostic products and partnerships, such as the collaboration with Audere for at-home self-collection solutions. The company is publicly traded on Nasdaq under the ticker LMDX, and it continues to expand its market presence by broadening access to a variety of testing needs.
Keywords: diagnostics, point-of-care, high-sensitivity, high-throughput, healthcare, nucleic acid, FDA, testing, platform, revenue.
Tech stack
Investments by LumiraDx
Edit